White House Backs Bayer's Bid for Supreme Court Review in Roundup Case
By Billy Gray
Bayer said it welcomed the U.S. Solicitor General's support for a Supreme Court review of a case that could curtail longrunning litigation regarding its Roundup pesticide.
The German life-sciences company said the government's support would be significant as the Court weighs its petition, arguing that federal pesticide law preempts state-level failure-to-warn claims. This could limit tens of thousands of lawsuits alleging that the company's Roundup weed-killer causes cancer.
Solicitor General D. John Sauer in a brief said that "[the Environmental Protection Agency] has repeatedly determined that glyphosate is not likely to be carcinogenic in humans, and the agency has repeatedly approved Roundup labels that did not contain cancer warnings."
Bayer previously stated that it aims to significantly contain Roundup litigation by the end of 2026.
Write to Billy Gray at william.gray@wsj.com
(END) Dow Jones Newswires
December 02, 2025 02:42 ET (07:42 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
This Once-Hot AI Stock Now Looks Deeply Undervalued
The 10 Best Companies to Invest in Now
He Tried Shorting Jim Cramer’s Stock Picks. It Cost Him More Than Money
United States